Navigation Links
Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
Date:3/23/2009

(exclude certain Asia-Pacific territories) to CXA-101 (FR264205) from Astellas Pharma Inc. in 2007. CXA-101's potent in vitro activity against Pseudomonas aeruginosa has the potential to address the unmet medical need posed by this very problematic gram-negative pathogen, which is a common cause of serious infection associated with high morbidity and mortality. Nonclinical studies have shown CXA-101 is highly active against multiple drug-resistant Pseudomonas aeruginosa, including many strains resistant to carbapenems, an antibiotic class generally considered as having the most potent activity against resistant gram-negative pathogens.

About Calixa Therapeutics

Calixa Therapeutics Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of infectious diseases. The company's initial focus is on developing novel antibiotics for use in the hospital setting. Calixa Therapeutics, which is privately held, is headquartered in San Diego and has operations in the San Francisco Bay Area. For additional information, please visit: www.calixainc.com.

    Contacts:

    Robert Flamm, Ph.D., or David Schull
    Russo Partners
    (212) 845-4226
    robert.flamm@russopartnersllc.com
    david.schull@russopartnersllc.com

    Eckard Weber, M.D.
    Calixa Therapeutics Inc.
    (858) 480-2420
    stone@domainvc.com


'/>"/>
SOURCE Calixa Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
2. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
3. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
4. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
5. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
6. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
7. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
8. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
9. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
10. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
11. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... July 30, 2015  Unichem Pharmaceuticals ( USA ... of Hydrochlorothiazide tablets 25 mg 1000-count bottle to the ... precautionary measure due to the identification of a Clopidogrel ... The risk associated with mistakenly taking a ... increased probability of experiencing Clopidogrel,s side effects which include ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... Ellman International, Inc., a New York based developer, manufacturer ... procedures, announced that Frank D. D,Amelio will join its ... (COO), Executive Vice President. "We are proud to welcome ... help guide the company,s continued growth," said Chief Executive ...
... This month, Minnesotans are recognized for their outstanding ... and for their donations of the blood component, plasma, ... Throughout September, Minnesota Gov. Tim Pawlenty is recognizing "Plasma ... to raise awareness for the rare, genetic diseases treated ...
Cached Medicine Technology:Ellman International Announces Executive Team Hire 2Minnesotans Help Produce As Well As Benefit from Lifesaving Therapies 2
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent ... Court in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini ... docket entry was made recording the minutes of the status conference, which was held ...
(Date:7/31/2015)... ... July 31, 2015 , ... People love to feel like ... where price is an important factor to clients when choosing to purchase a ... the Preferred Producer Multi-Life Discount program, where advisers pass savings onto their clients. ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error on ... by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, ... drug, biologic and device firms reduce manufacturing errors by 50 percent or more, ...
(Date:7/30/2015)... ... 2015 , ... As more hospitals across the country see the value in ... challenge. Because of growing competition, it is more important than ever to market ... The team at Wound Care Advantage has found that while many hospitals ...
(Date:7/30/2015)... Miami, FL (PRWEB) , ... July 30, 2015 ... ... a new online program entitled " Lovetraction Lines ." It's for women interested ... in the men they desire. The course, which officially launched to the public ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2
... real-time imaging and image guidance systems for use in,the operating room, will be holding its annual ... DATE: May ... 9:30 am, Eastern Daylight Time, LOCATION: ... 150 King Street West ...
... Using ... ImmunoCAP -, PORTAGE, Mich., May ... and Clinical Immunology revealed variations in,the results of three common allergy diagnostic ... specialists at,Mount Sinai School of Medicine, determined that the laboratory results from,two ...
... May 8 In March, AHIP,s Board of,Directors ... the,Medicare Advantage and Medicare Part D plan marketing ... issued its new regulations., (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ... to ensure beneficiaries can rely on the,information being ...
... prolongs the life of these growth-driving molecules in breast ... Emory University,s Winship Cancer Institute. , The results are ... journal Molecular Cell. , Most breast cancers contain estrogen ... of the hormone estrogen. Their presence can determine whether ...
... May 8, 2008 People with diagnosed diabetes are nearly ... by arthritis hinders the successful management of both diseases, according ... released today by the Centers for Disease Control and Prevention ... kind to look at the relationship between arthritis and diabetes ...
... Neuroscientists at Johns Hopkins have discovered that mice ... exhibit a number of schizophrenia-like behaviors. The finding ... in the development of schizophrenia and related psychiatric ... for developing therapies. , The BACE1 enzyme, ...
Cached Medicine News:Health News:Novadaq Technologies Notice of Annual Meeting 2Health News:Novadaq Technologies Notice of Annual Meeting 3Health News:Data Show Common Allergy Tests Are Not Interchangeable 2Health News:Data Show Common Allergy Tests Are Not Interchangeable 3Health News:Previously unseen switch regulates breast cancer response to estrogen 2Health News:New report: Arthritis is a potential barrier to physical activity for adults with diabetes 2Health News:Hopkins researchers discover new link to schizophrenia 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: